Unfortunately, mg, you are correct.
The confirmation of the death of the Banyan deal (predicted by yours truly some months ago to a chorus of insults) yields no reasonable positive interpretation. It indicates that the staffing business is not worth what Banyan reportedly was willing to pay. The staffing business produces very little in earnings, and is therefore not worth much.
An investment by a mutual fund is simply the next fool's gold discovered amongst this rubble. Keep spinning the tales and you may fool some of the people.
The Cymedix product may be worth what Mike Moran states, but there exists no independent support for this valuation.
There is no capital to support the product's development. The likelihood is that, if capital is to be found, it will be highly dilutive to current shareholders.
The likelihood remains, in my mind, that much of the posting on this thread is hype. Possible too is that the Banyan deal was a sham. Does Banyan even exist? (BTW, it's address is a hotel, I've heard) I doubt that anyone can find any substantive information in this regard.
There has been no positive news of substance in the four months I have owned this stock, and I expect there will be none in the future. No actual product sales, no cash infusions, no earnings, et cetera.
The news of substance is all bad - delisting, cancellation of cash infusion.
Please, prove me wrong. But if you have nothing to say of substance then please do not respond to this post at all. Mike - I request that you do not respond at all.
Peter Michaelson |
